I assume the OLE data will be excluded because it was not blinded and not described as part of the Phase 2b/3 trial.
However the data from the 48 week trial has been refined through precision genomic based analysis to produce the ABCLEAR1-3 data which is outstanding. Not new data just a better focus on its details.